Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.

Evon, Donna M; Lin, Hsing-Hua S; Khalili, Mandana; Wahed, Abdus S; Yim, Colina; Fontana, Robert J; Hoofnagle, Jay H

Evon, Donna M; Lin, Hsing-Hua S; Khalili, Mandana; Wahed, Abdus S; Yim, Colina; Fontana, Robert J; Hoofnagle, Jay H.

Afiliação

Evon DM; Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Donna_evon@med.unc.edu.
Lin HS; Departments of Epidemiology and Biostatistics, University of Pittsburgh, Pittsburgh, USA.
Khalili M; Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, USA.
Wahed AS; Department of Medicine, University of California at San Francisco, San Francisco, USA.
Yim C; Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA.
Fontana RJ; Toronto Centre for Liver Disease, University of Toronto, Toronto, Canada.
Hoofnagle JH; Department of Internal Medicine, University of Michigan, Ann Arbor, USA.

Dig Dis Sci ; 68(12): 4499-4510, 2023 12.

Article em En | MEDLINE | ID: mdl-37804353

Assuntos

Antivirais; Hepatite B Crônica; Humanos; Masculino; Adulto; Feminino; Tenofovir/efeitos adversos; Antivirais/efeitos adversos; Antígenos E da Hepatite B; DNA Viral; Vírus da Hepatite B/genética; Resultado do Tratamento; Hepatite B Crônica/diagnóstico; Biomarcadores

Palavras-chave

Instrument; Measure; Patient-reported outcomes, liver; Questionnaire; Randomized controlled trial; Survey

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite B Crônica Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google